RT Journal Article
SR Electronic
T1 Advances in atopic dermatitis
JF Clinical Medicine
JO Clin Med
FD Royal College of Physicians
SP 177
OP 181
DO 10.7861/clinmed.2021-0280
VO 21
IS 3
A1 Alice Plant
A1 Michael R Ardern-Jones
YR 2021
UL http://www.rcpjournals.org/content/21/3/177.abstract
AB Atopic dermatitis (AD) is a common inflammatory skin disease characterised by itch and is responsible for significant reduction in quality of life. While AD primarily arises in those under the age of 2 years, it is frequently persistent into adulthood. Recognition of AD is important for the general physician, especially to distinguish causes of acute flares that may present in any medical setting, such as eczema herpeticum and associated allergic reactions. While, to date, treatments have largely focused on broad spectrum immunomodulation with corticosteroids or systemic therapies (such as ciclosporin and methotrexate), increased knowledge in the pathophysiology of the disease has recently led to the expansion of treatment options available for those suffering with AD, and the new drugs on the horizon promise a previously unimagined potential for effective and safe treatment.